BIOMAT Database Logo BIOMAT Database Logo

Failure of long-term therapy with sodium valproate in Cushing's disease. 1997

A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Napoli, Italy.

The aim of the current study was to evaluate the effectiveness of a long-term treatment with sodium valproate in 19 patients with Cushing's disease. Before therapy beginning, the patients were subjected to acute test with 600 mg sodium valproate. Then, they were subjected to a 3-month therapy with sodium valproate at the dose of 600 mg/day before surgery (presurgical study). The 7 patients not surgically cured were subjected again to a 3-month therapy with sodium valproate at the dose of 600 mg/day after surgery (postsurgical study). Circulating ACTH and cortisol and urinary free cortisol levels were evaluated before and monthly after the beginning of the therapy. A decrease of plasma ACTH and serum cortisol levels greater than 50% of baseline was considered as positive response to acute test whereas the normalization of plasma ACTH, serum cortisol and urinary free cortisol levels and the clinical remission were considered as positive response to the long-term treatment. At acute test, 8 patients were considered responders and 11 patients non-responders. In no patient plasma ACTH, serum cortisol and urinary free cortisol were normalized during the long-term treatment. Urinary free cortisol levels significantly decreased (483.2 +/- 33.8 vs 699.4 +/- 67.0 micrograms/24 h), whereas plasma ACTH (302.8 +/- 17.7 vs 183.3 +/- 25.0 ng/l) and serum cortisol (466.5 +/- 23.2 vs 356.7 +/- 19.6 micrograms/l) significantly increased during sodium valproate administration in the 19 patients enrolled in the presurgical study. Plasma ACTH (247.7 +/- 22.3 vs 168.6 +/- 15.0 ng/l), serum cortisol (387.4 +/- 35.8 vs 282.0 +/- 16.0 micrograms/l) and urinary free cortisol (370.9 +/- 70.6 vs 261.3 +/- 37.8 micrograms/24 h) levels significantly increased in the 7 patients enrolled in the postsurgical study. No patient had clinical remission of Cushing's disease. In conclusion, the current study showed that long-term therapy with sodium valproate is not useful in the therapeutic management of Cushing's disease neither as alternative nor as adjunctive therapy to surgery.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003480 Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. Cushing's Syndrome,Hypercortisolism,Syndrome, Cushing,Syndrome, Cushing's
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000324 Adrenocorticotropic Hormone An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). ACTH,Adrenocorticotropin,Corticotropin,1-39 ACTH,ACTH (1-39),Adrenocorticotrophic Hormone,Corticotrophin,Corticotrophin (1-39),Corticotropin (1-39),Hormone, Adrenocorticotrophic,Hormone, Adrenocorticotropic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014635 Valproic Acid A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS. Dipropyl Acetate,Divalproex,Sodium Valproate,2-Propylpentanoic Acid,Calcium Valproate,Convulsofin,Depakene,Depakine,Depakote,Divalproex Sodium,Ergenyl,Magnesium Valproate,Propylisopropylacetic Acid,Semisodium Valproate,Valproate,Valproate Calcium,Valproate Sodium,Valproic Acid, Sodium Salt (2:1),Vupral,2 Propylpentanoic Acid
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures

Related Publications

A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
Sodium valproate in Cushing's disease.
July 1984, Lancet (London, England),
A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
Long term bromocriptine therapy in Cushing's disease.
January 1982, Journal of endocrinological investigation,
A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
Sodium valproate and metyrapone for pituitary-dependent Cushing's disease.
September 1984, Lancet (London, England),
A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
[Clinical remission in Cushing's disease through treatment with sodium valproate and bromocriptine].
January 1991, Revista clinica espanola,
A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
Long-term treatment of Nelson's syndrome with sodium valproate.
February 1988, Clinical endocrinology,
A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
Edema associated with long-term valproate therapy.
January 1990, Epilepsia,
A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
Cyclical Cushing's disease and its successful control under sodium valproate.
December 1990, Journal of endocrinological investigation,
A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
The effect of sodium valproate in Cushing's disease, Nelson's syndrome and Addison's disease.
August 1988, Klinische Wochenschrift,
A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
[Therapy of generalized epilepsies with long-term EEG guided single dose administration of sodium valproate].
August 1983, Der Nervenarzt,
A Colao, and R Pivonello, and F S Tripodi, and F Orio, and D Ferone, and G Cerbone, and C Di Somma, and B Merola, and G Lombardi
Hematologic manifestations of long-term valproate therapy.
January 1993, Epilepsia,
Copied contents to your clipboard!